SCHEMBL30052277

SCHEMBL30052277

CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 1/20 0.44
▸ ACE P12821 1/20 0.44
▸ CPA1 P15085 1/20 0.44
▸ ACE2 Q9BYF1 1/20 0.44
▸ TSHR P16473 2/20 0.43
▸ CTSS P25774 1/20 0.40
▸ CTSK P43235 1/20 0.40
▸ GLO1 Q04760 1/20 0.38
▸ PTGS1 P23219 1/20 0.37
▸ GSTK1 Q9Y2Q3 1/20 0.37
▸ ANPEP P15144 1/20 0.37
▸ FNTA P49354 2/20 0.37
▸ FNTB P49356 2/20 0.37
▸ PGGT1B P53609 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ METAP2 P50579 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30052724 0.88 TSHR (0.42) TSHRCTSSCTSKGLO1PTGS1
SCHEMBL29929905 0.87 TSHR (0.41) TSHRCTSSCTSKGLO1PTGS1
SCHEMBL30051726 0.85 FNTA (0.44) FNTAFNTBPGGT1BLMNA
SCHEMBL29723030 0.85 MME (0.48) MMEACECPA1ACE2GLO1
SCHEMBL2550262 0.85 FNTA (0.45) FNTAFNTBPGGT1BLMNA
SCHEMBL30052069 0.85 TSHR (0.44) TSHRCTSSCTSKGLO1PTGS1
SCHEMBL8333718 0.85 FNTA (0.45) FNTAFNTBPGGT1BLMNA
SCHEMBL13093070 0.85 FNTA (0.45) FNTAFNTBPGGT1BLMNA
SCHEMBL2550265 0.85 FNTA (0.45) FNTAFNTBPGGT1BLMNA
SCHEMBL30051678 0.83 MME (0.46) MMEACECPA1ACE2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 — — US disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP MME 824/4885ACE 1190/4885CPA1 245/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD MME 105/4885ACE 486/4885CPA1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback